Huzhou Shenke
Advancing biological innovation through precision detection and standardized kits
Advancing biological innovation through precision detection and standardized kits
Huzhou Shenke is a company that is focused on advancing biological innovation through precision detection and standardized kits. Established in 2012, the company is engaged in the research and development of common key technologies and products in the field of biological products, particularly in the Biopharma, Biotechnology, and Pharmaceutical industries.
They specialize in providing detection technical services and standardized detection kits, with a focus on host cell nucleic acid. In January 19, 2023, the company secured a significant Series B investment, with contributions from notable investors including CITIC Capital, CLSA Capital Partners, Riverhead Capital Investment Management, CICC, and GoldStone Investment.
This injection of capital is a strong indication of the confidence that these prominent investors have in Huzhou Shenke's vision and potential for growth within the biotech and pharmaceutical sectors. With this recent backing, the company is well-positioned to continue making strides in advancing biological innovation and contributing to the evolution of the industry through their focus on precision detection and standardized kits.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | Unknown | 5 |
|
19 Jan 2023 |
No recent news or press coverage available for Huzhou Shenke.
We care about your data, and we'd love to use cookies make your experience better.